Mel Mann, Patient Advocate, Chronic Myeloid Leukemia Survivor, shared on X:
“Personalized mRNA vaccines just cleared a major hurdle.
In the phase 3 INTerpath-001 trial, adding intismeran autogene to pembrolizumab cut the risk of recurrence or death by 42% in high-risk resected melanoma versus immunotherapy alone.
Manufacturing success rate: over 99%. This is one of the first clear signals that individualized neoantigen approaches can work at scale.”
You can also read:
INTerpath-001 Trial: Personalized mRNA Cancer Vaccine in High-Risk Melanoma
